Rezatapopt and the Return of Targetable p53

References

[1] E. E. Dumbrava, G. I. Shapiro, A. R. Parikh, et al., “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” New England Journal of Medicine 394, no. 9 (2026): 872–883.

[2] D. P. Lane, “Cancer. P53, Guardian of the Genome,” Nature 358, no. 6381 (1992): 15–16.

[3] A. J. Levine, J. Momand, and C. A. Finlay, “The p53 Tumour Suppressor Gene,” Nature 351, no. 6326 (1991): 453–456.

[4] K. H. Vousden and D. P. Lane, “p53 in Health and Disease,” Nature Reviews Molecular Cell Biology 8, no. 4 (2007): 275–283.

[5] J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine, “The Mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation,” Cell 69, no. 7 (1992): 1237–1245.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.